02616.HK
CStone Pharmaceuticals
HKSE · Healthcare · Biotechnology · CN
HKD 4.94
+4.33%Oct 26, 2026, 05:01 UTC
CStone Pharmaceuticals Co. Ltd. presented clinical validation data for its CS2009 antibody at the 2026 ESMO Congress, reporting data from more than 300 participants across solid tumors and validation of its mechanism, safety, and clinical concept.
Source:Sep 24, 2026, 13:16 UTC
CStone Pharmaceuticals CEO, R&D President and Executive Director Yang Jianxin bought a total of 496,000 shares of the company on the open market between September 17 and 22 with his own funds for over HK$2.7 million, raising his stake to about 5.31%.
Source:Aug 27, 2026, 11:39 UTC
CStone Pharmaceuticals reported interim results for the six months ended June 2026, with revenue of RMB 205 million, up 315% year-on-year, and a narrowed net loss of RMB 252 million.
Source:Jul 22, 2026, 23:39 UTC
CStone Pharmaceuticals repurchased 4.597 million shares in the open market last month, all intended for cancellation.
Source: